Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 3/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909143 | 1.00 | ALDH1A1 (0.55) | ALDH1A1KMT2ALMNAMEN1GRM5 | |
| SCHEMBL5744752 | 1.00 | ALDH1A1 (0.55) | ALDH1A1KMT2ALMNAMEN1GRM5 | |
| SCHEMBL14731432 | 0.92 | ALDH1A1 (0.61) | ALDH1A1KMT2ALMNAMEN1GRM5 | |
| Trifluoroacetic Acid SCHEMBL3857570 | 0.92 | KCNH2 (0.48) | ALDH1A1KMT2ALMNAMEN1GRM5 | |
| SCHEMBL2431433 | 0.92 | GRM5 (0.53) | ALDH1A1KMT2ALMNAMEN1GRM5 | |
| SCHEMBL12426729 | 0.84 | KCNH2 (0.50) | GRM5KDM1AKCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL26944349 | 0.84 | GRM5 (0.54) | ALDH1A1KMT2ALMNAMEN1GRM5 | |
| SCHEMBL5908999 | 0.84 | ALDH1A1 (0.61) | ALDH1A1KMT2ALMNAMEN1GRM5 | |
| SCHEMBL26421666 | 0.83 | KCNH2 (0.44) | GRM5KDM1AKCNH2L3MBTL3L3MBTL1 | |
| SCHEMBL26421617 | 0.83 | ALDH1A1 (0.47) | ALDH1A1GRM5KDM1AKCNH2L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | claimed |
| US-7592466-B2 | Ureas having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1680415-B1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | ABBVIE INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1680415-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | HAVIV FORTUNA | 2006-02-09 | — | — | US | disclosed |
| WO-2005035524-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENSIS INHIBITORS | ABBOTT LABORATORIES (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | ALDH1A1 206/4885KMT2A 3266/4885LMNA 3306/4885 |
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | ALDH1A1 206/4885KMT2A 3266/4885LMNA 3306/4885 |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | FLT4, FLT1, KDR | ALDH1A1 1710/4885KMT2A 4101/4885LMNA 2101/4885 |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | FLT4, KDR, FLT1 | ALDH1A1 424/4885KMT2A 3317/4885LMNA 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.